Analytical Evaluation of a Presepsin Assay for Specimen Stability

Presepsin, a fragment of the CD14 protein identified as a soluble subtype, emerges as a promising biomarker for sepsis diagnosis and prognosis [4-7].Secreted by lipopolysaccharide-recognizing activated monocytes, presepsin offers advantages over existing markers like procalcitonin and C-reactive protein, reportedly releasing earlier and reaching peak concentrations faster [4, 8, 9].Presepsin's potential as a prognostic marker has recently gained traction, particularly for coronavirus disease-2019 (COVID-19) patients.Studies have demonstrated its ability to enhance outcome prediction when combined with clinical indices, exceeding the accuracy of clinical indices alone [10].Presepsin levels in moderate COVID-19 cases were significantly higher than in mild cases, suggesting its value in guiding treatment and prognosis decisions [11].Moreover, presepsin levels have shown promise in predicting septic acute kidney injury [12].Rapid turnaround times are crucial for sepsis diagnostic biomarkers.However, situations arise where limited laboratory resources necessitate test transfer to reference laboratories.